Objective: The prevalence of hepatitis C virus (HCV) infection in Canada is estimated to be 1% and expected to increase during the next decade. Mental illness, particularly depression, is common among HCV-infected patients and remains an obstacle to interferon-alpha (IFN-a) treatment. We summarize the risk factors for interferon-a-induced major depressive disorder (IFN-a-MDD) in HCV patients and the evidence for antidepressant prophylaxis and symptomatic antidepressant treatment of depression.
S ince its isolation in 1989, HCV has grown as a public health concern and infected about 250 000 Canadians and more than 140 million people worldwide. 1 Currently, the most common mode of transmission is IDU, accounting for 65% to 70% of cases. 2 Other risk factors for HCV include high-risk sexual activity, occupational exposure, intranasal cocaine use, blood products before July 1992, long-term hemodialysis, and children born to women who are HCV positive. 2 Up to 85% of patients with acute HCV will develop chronic HCV infection and nearly 20% of these patients will develop liver cirrhosis. 3, 4 In North America, genotypes 1, 2, and 3 constitute nearly all HCV infections, with genotypes 4, 5, and 6 mainly found in Egypt, South Africa, and Southeast Asia, respectively. Current treatment of HCV involves combination weekly intramuscular pegIFN-a and daily oral ribavirin for 24 weeks for genotype 2 and 3, and 48 weeks for genotype 1. 5 Response to combination HCV treatment is measured by SVR rates, defined as undetectable HCV levels 6 months postimmunotherapy. With pegIFN-a treatment, SVR rates approach 50% for genotype 1 and about 80% for genotypes 2 and 3. 4 Despite improved SVR rates with the evolution of HCV therapy, treatment continues to be limited by neuropsychiatric complications that can lead to HCV treatment discontinuation in up to 16% of patients. 6 Similar to other chronic illnesses, HCV infection is associated with higher rates of depression. Lee et al 7 found evidence of depressive symptoms in about 24% of patients with untreated hepatitis C, with two-thirds requiring antidepressant treatment. Moreover, rates of depression in HCV-infected military veterans' populations vary from 34% to 62%. [8] [9] [10] Johnson et al 11 argue that rates of depression may be inflated in veterans patient populations or secondary to comorbid IDU. However, a prospective study 12 of 135 HCV patients without a lifetime history of substance use, revealed a significantly higher number of lifetime diagnoses of MDD, compared with control subjects. Despite these increased rates of comorbid depression, about 85% of HCV-infected patients continue to suffer from unrecognized mental disorders in prospective studies. 13, 14 Further complicating the risk of depression is the occurrence of IFN-a-MDD during HCV treatment, with estimated prevalence rates ranging from 10% to 40% in the literature and about 33% of patients in more rigorous studies. [15] [16] [17] [18] Rates of depression during IFN-a treatment vary owing to the definition of depression used in these studies and tend to be lower rates when using categorical (that is, diagnostic criteria), compared with symptomatic or scale-based approaches. Moreover, the classification of IFN-a-MDD within the major depression syndrome is problematic, as presentations of IFN-a-MDD often consist of mild mood changes and prominent neurovegetative symptoms. 19 Nonetheless, evidence suggests that nearly 75% of patients who develop IFN-a-MDD, as per structured psychiatric interview or clinician-rated scales, do so within the first 8 weeks of the HCV treatment course, which appears to be the high-risk period both for depressive symptoms and for suicidal ideation. 17, 20 The development of depression during HCV treatment is serious as it could require a dose reduction in IFN-a, thus reducing HCV treatment effectiveness and lower the likelihood of SVR, or result in discontinuation of IFN-a treatment in severe cases precluding SVR.
Conversely, psychiatric patient populations appear to be more susceptible to HCV infection. Studies have found increased rates of HCV in psychiatric inpatients, patients with bipolar disorder, and clozapine-treated patients with psychotic disorders. [21] [22] [23] Rosenberg et al 24 reported an 11-fold increase in the prevalence of HCV infection in patients suffering from mental illness, compared with the general US population. Further research is required to determine the effect of comorbid substance use on HCV prevalence rates in this patient population.
Despite the significant comorbidity between HCV infection and depression, the presence of a mental illness remains a barrier to HCV treatment for many patients. In a large prospective study of 4084 veterans, about 18% of veterans were excluded from receiving HCV treatment owing to pre-existing psychiatric disease. 25 Although numerous studies demonstrate no difference in IFN-a treatment adherence or SVR rates between depressed HCV patients, compared with control subjects, HCV treatment guidelines continue to caution against HCV treatment in depressed HCV patients. 5, [26] [27] [28] [29] For example, the Canadian consensus guidelines for the treatment of HCV list major depression as a relative contraindication, in addition to active psychoses. These recommendations contradict recent evidence, which demonstrates no significant difference in HCV treatment outcomes for patients with mental illness who are provided appropriate mental health follow-up and services. 30 With depression emerging as a key factor influencing HCV treatment outcomes, several studies have focused on the etiology and treatment of IFN-a-MDD. Specific antidepressant strategies for IFN-a-MDD may include either symptomatic or prophylactic (that is, antidepressant pretreatment prior to starting IFN-a) treatment approaches. Our systematic review will provide an overview of IFN-a-MDD risk factors, proposed mechanism of action, and a summary of the evidence for using symptomatic and prophylactic antidepressant during HCV immunotherapy. For the purpose of this review, the term depression will be differentiated from depressive symptomatology and will refer exclusively to major depressive episodes in the context of IFN-a therapy.
Methods
We performed a comprehensive search of MEDLINE, EMBASE, and CINAHL from 1988 to 2008 (April) and limited results to the English language and human studies. The following search terms were entered: hepatitis C, interferonalpha, depression, major depressive disorder, mood disorders, psychotropic agents, and antidepressive agents. We hand-searched listed references in HCV review articles and letters to the editors for additional studies pertaining to IFN-a-MDD and its treatment. The study inclusion criteria included: RCT or quasi-experimental studies with at least 2 comparison groups evaluating antidepressant prophylactic (antidepressant treatment initiated prior to IFN-a therapy) or symptomatic (antidepressant initiated after depressive symptoms emerge during IFN-a therapy) treatment; the use of longitudinal objective measures to assess depressive symptoms (at least 1 measure pre-and 1 measure during IFN-a treatment); and a minimum of 10 subjects in the study sample. A total of 172 studies were identified in the initial search but only 8 studies met the inclusion criteria (6 prophylactic trials and 2 symptomatic trials). Table 1 summarizes the 6 prophylactic antidepressant trials for IFN-a-MDD and all uncontrolled prospective studies and anecdotal reports will be summarized in the respective sections of the review. Pharmacological agents reported to be beneficial in excluded studies and anecdotal reports are briefly discussed in this review ( Table 2 ). Based on the literature, we will also review the risk factors and propose a model for IFN-a-MDD ( Figure 1 ).
Risk Factors of IFN-a-Induced Depression
Myriad risk factors for IFN-a-MDD in HCV-infected patients are cited in the literature. Unfortunately, studies have yielded limited and inconclusive findings. Only elevated baseline depressive symptoms pre-HCV treatment was found to be a robust predictor of IFN-a-MDD. [31] [32] [33] [34] In 2 studies of 23 and 36 HCV patients receiving IFN-a, baseline BDI, and baseline HDRS scores were the best predictors of depressive symptoms emerging as quickly as 1 month after starting IFN-a treatment. 35, 36 The emergence of neurovegetative symptoms as early as the first week of immunotherapy may also confer an increased risk of cognitive-depressive symptoms developing during HCV treatment. 37 Although pre-HCV treatment and early depressive symptoms are important risk factors for IFN-a-MDD, the presence of baseline depressive symptoms did not correlate with higher rates of HCV treatment discontinuation in a sample of intravenous drug users. 38 Dell'Osso et al 39 reported an increased risk of IFN-a-MDD in HCV patients with a lifetime history of subthreshold manic-hypomanic symptoms and suggests that HCV patients be screened for a history of mood dysregulation prior to IFN-a therapy. Other proposed risk factors include increased age, a past history of depression, a history of any psychiatric or neurologic illness, a family history of a mood disorder, and an increased ribavirin dose; however, these results have not been confirmed in other prospective studies. 17, 32, [40] [41] [42] Despite early studies identifying high-dose IFN-a as a risk factor for IFN-a-MDD in HCV patients, several studies have refuted this finding. 26, 43, 44 Depression secondary to IFN-a therapy may also be a result of 5-HT deficiency and altered 5-HT metabolism. In a study by Bonaccorso et al, 31 attenuated serum 5-HT and TRP levels owing to activation of IDO, a TRP-catabolizing enzyme, were correlated with increased MADRS scores during IFN-a therapy. Wichers et al 45 proposed a neurotoxic model for IFN-a-MDD based on their findings of IDO hyperactivity resulting in an increased production of quinolinic acid, a neurotoxic metabolite. Interestingly, kynurenine (a TRP metabolite) and TRP levels appear to normalize after successful treatment of HCV with IFN-a and were associated with a reduction in psychopathology. Based on a study of 18 patients receiving IFN-a for HCV, Russo et al 47 argued that TRP catabolism was linked to IFN-a-induced irritability and not to depression. This same study also demonstrated a decrease in platelet 5-HT levels during HCV treatment, suggesting a reduction in both central and peripheral synthesis of 5-HT.
Evidence of 5-HT dysregulation has also been supported by genetic studies examining the effect of genetic polymorphisms on the risk of IFN-a-MDD. Kraus et al 48 showed a correlation between allelic variation in 5-hydroxytryptamine receptor 1 autoreceptor expression and increased depressive scores on the HADS. Animal studies have shown an upregulation of 5-HT transporter messenger ribonucleic acid in response to IFN-a; however, human studies of HCV patients have failed to replicate these findings. 48, 49 The overlap between the concept of cytokine-induced sickness behaviour, which is defined as anhedonia, anorexia, and decreased social exploration, and depression, has generated research interest in the role of cytokines in IFN-a-MDD. 50, 51 Although 1 retrospective study found reduced HCV treatment response rates in patients who developed IFN-a-MDD, 2 prospective studies demonstrated increased HCV treatment response rates in depressed patients and theorized that increased immune activation precipitated depression in IFN-a-treated patients. 34, 52, 53 However, a study of 39 patients with IFN-a-MDD demonstrated an increase in SVR in depressed patients treated with antidepressant therapy and suggested that antidepressants may play a role in the relation between SVR and depression by alleviating inflammatory cytokine activity. 52 Moreover, studies have linked changes in specific ILs to the onset of IFN-a-MDD. 54 Correlations between elevated IL-2, -6, and -10 levels and increased MADRS scores have been observed in HCV patients undergoing immunotherapy. 54, 55 Further support for cytokine involvement extends from research linking low levels of dipeptidyl-peptidase 4, a membrane-bound serine protease with potential psychoneuroimmune activity, to increased MADRS scores and TRP catabolism following prolonged IFN-a exposure. 56 In a study 55 of 17 HCV patients exposed to IFN-a, proinflammatory cytokines and not daily average cortisol levels were significant predictors of IFN-a-MDD.
Preliminary studies have purported that key personality features may also predispose patients to developing depression during HCV treatment. Loftrich et al 36 identified baseline neuroticism and low agreeableness as risk factors for IFN-a-MDD in 23 HCV patients. In a study 57 of 87 HCV patients undergoing IFN-a treatment, elevated scores on the State-Trait Anger Expression Inventory were correlated with higher depressive symptoms and lower quality of life during the course of treatment.
Given the existing literature, baseline depression appears to be the most reliable predictor of depression during IFN-a treatment. Therefore, routine screening and monitoring of depressive symptoms for at-risk patients is integral to the identification and treatment of high-risk patients. Standardized self-report scales for depression, such as the CES-D, the BDI, and the HADS, and clinician-rated scales, such as the MADRS and HDRS, have been used to monitor depressive symptoms in this patient population. 32, [58] [59] [60] [61] [62] [63] [64] [65] [66] Larger studies are required to further delineate specific risk factors for IFN-a-MDD to inform prophylactic, compared with symptomatic antidepressant, treatment approaches.
Treatment of IFN-a-Induced Depression in HCV Patients
Although most patients develop IFN-a-MDD within the first 12 weeks of HCV treatment, 2 distinct dimensions of depression emerge during IFN-a treatment for HCV: a neurovegetative syndrome and a depression-specific syndrome. 50 The neurovegetative syndrome consists of reduced energy, anorexia, and psychomotor retardation, while the depression specific syndrome consists of depressed mood, anxiety, and the cognitive disturbances of depression. In addition to depression phenomenology, the onset of these depression subsyndromes also differs during IFN-a therapy for HCV. The neurovegetative syndrome appears within the first few months of IFN-a treatment, while the depressionspecific syndrome emerges months later during the treatment course. 50 Despite the overlap between the neurovegetative symptoms of IFN-a therapy and depression, the beneficial effects of SSRIs are primarily limited to depression-specific symptoms and have minimal effectiveness for specific neurovegetative symptoms. Antidepressant agents with dopamine or norepinephrine effects, such as venlafaxine, theoretically could ameliorate the neurovegetative dimensions of this syndrome; however, there are no studies in HCV patient populations to confirm this hypothesis. The remainder of this section focuses on the evidence for prophylactic antidepressant use, compared with symptomatic antidepressant treatment approaches, and will include a summary of potential antidepressant complications unique to HCV treatment.
Antidepressant Prophylaxis for IFN-a-Induced Depression
In a seminal study, Musselman et al 94 evaluated the efficacy of antidepressant prophylaxis treatment for IFN-a-related depressive symptoms in malignant melanoma patients. Although this study showed a reduction in depressive symptoms with paroxetine prophylaxis, the doses of IFN-a used in the treatment of malignant melanoma are much higher than in HCV treatment and limit generalization of study findings to HCV patients. More recent studies involving HCV patients have provided much needed data on the efficacy of prophylactic antidepressant treatment for IFN-a-MDD (Table 1) .
Several studies have focused primarily on prophylactic treatment with SSRIs for preventing IFN-a-MDD. During a 24-week study of 61 HCV patients, Raison et al 58 randomized patients to pretreatment with paroxetine or placebo in a double-blind fashion. Although rates of major depression were not statistically different between the groups (paroxetine = 10%, placebo = 21%), rates of moderate or severe depression, defined as MADRS scores of 25 or more, were significantly greater in the placebo group (paroxetine = 9%, placebo = 28%). A second RCT evaluating the efficacy of paroxetine pretreatment for IFN-a-related depressive symptoms also revealed no significant difference in the rates of depression in 33 HCV patients. 18 Following prophylactic treatment with paroxetine at a mean dose of 34.4 mg daily, about 36% developed IFN-a-MDD, compared with 32% in the placebo arm. It should be noted that the 10 of the 11 patients who developed depression in the rescue arm achieved remission of depression with paroxetine treatment.
An open-label prospective study 68 of 36 patients revealed a significant decrease in the number of IFN-a-induced major depressive episodes following citalopram prophylaxis (14%), compared with patient groups with (64%) and without psychiatric disorders (55%) who did not receive antidepressant pretreatment.
Preliminary studies also support the use of prophylactic antidepressant treatment for patients with a previous history of IFN-a-MDD or MDD prior to starting IFN-a re-therapy. A pilot study 69 of 10 HCV patients with a diagnosis of MDD currently in remission and receiving pretreatment, with escitalopram 10 mg daily, showed no significant increase in HDRS scores during the course of IFN-a re-treatment. In an open-label controlled trial, Kraus et al 70 examined the efficacy of either citalopram or paroxetine pretreatment in HCV patients with a history of IFN-a-MDD that resulted in IFN-a discontinuation. Patients receiving antidepressant treatment were compared with a control group consisting of HCV patients who had failed standard IFN-a therapy for reasons other than depression and agreed to pegIFN-a re-treatment. Prophylactic SSRI treatment resulted in significantly lower HADS depression scores and permitted 7 out of 8 patients with a preexisting history of IFN-a-MDD to complete HCV treatment. Therefore, SSRI pretreatment may be a viable option for patients who previously failed HCV treatment owing to depression.
Moreover, IFN-a therapy has been associated with altered dopamine function and overstimulation of hippocampal NMDA receptors, and generated interest in amantadine, an NMDA receptor antagonist, as a prophylactic agent to prevent IFN-a-MDD. 45, 71, 72 Quarantini et al 73 studied 14 HCV-infected patients treated with pegIFN-a, who were randomized to an amantadine treatment or an untreated control group during a 24-week follow-up period. Although this study was limited to a single-blind design, a significant increase in depressive symptoms was observed in the control group and not the amantadine pretreatment group. Kronenberger et al 74 also examined the effects of amantadine on depressive symptoms, which was identified as a secondary outcome measure in their study. Amantadine pretreatment, compared with placebo, resulted in significantly lower depressive symptoms on the Profile of Mood States scale at 24 weeks but not at 48 weeks of IFN-a treatment. Additional properties of amantadine, including its antiviral activity and fatigue reducing effects, further confound the results of these studies. 72, 75 
Symptomatic Treatment of IFN-a-Induced Depression
Several drugs have shown effectiveness in treating IFN-a-MDD in HCV patients; however, the evidence is predominantly limited to case studies. [76] [77] [78] The only published double-blind RCT involved 29 HCV patients treated with citalopram 20 mg daily for IFN-a-MDD and showed a significant decline in depressive symptoms as measured by the HADS. 64 Moreover, study blinding was discontinued prematurely owing to early emergence of significant depressive symptoms in the placebo arm, with 5 patients requiring rescue treatment with citalopram. The study showed no significant difference in IFN-a treatment completion rates and SVR rates between the groups.
Additional pharmacological agents studied to treat IFN-a-MDD include sertraline, nortriptyline, paroxetine, fluoxetine, mirtazapine, bupropion, imipramine, escitalopram, and venlafaxine (Table 2) . 32, 33, [79] [80] [81] [82] [83] [84] Prospective studies have shown that escitalopram and citalopram were well tolerated in HCV patients and antidepressant plasma levels were not significantly elevated in treated patients. 84, 85 Further, cases of IFN-a-MDD with psychotic features have responded to either venlafaxine or citalopram in combination with olanzapine treatment. 78, 86 Electroconvulsive therapy successfully treated 2 patients with major depression with psychotic features, with the first patient presenting during the course of HCV immunotherapy and the second patient developing symptoms 6 days after discontinuing IFN-a therapy. 87, 88 In the former case, the patient was maintained on mirtazapine 30 mg daily, sertraline 200 mg daily, and quetiapine 200 mg daily on an outpatient basis. Further, 2 of these 3 cases of psychotic depression secondary to IFN-a To date, few studies involving novel pharmacological agents for treating IFN-a-MDD exist in the literature. Weak dopamine antagonists, such as amisulpride, sulpiride, and levosulpiride, possess antidepressant properties and may be beneficial in managing depressed HCV patients during immunotherapy. 17, 76 Martin et al 89 showed a small but statistically significant change in IFN-a-induced fatigue following treatment with modafinil, but failed to demonstrate a significant reduction in BDI scores during the course of immunotherapy. Further studies examining the efficacy of these agents in HCV patients are needed.
IFN-a-Induced Depression Treatment Complications
Although amelioration of IFN-a depressive symptoms can be achieved with antidepressant medications, clinicians must be cognizant of drug adverse effects unique to HCV patients.
Rare risks of bone marrow suppression associated with mirtazapine or quetiapine may hypothetically increase the preexisting risk of agranulocytosis related to IFN-a therapy. 90, 91 Bupropion was well tolerated in an HCV patient with IFN-a-MDD; however, concomitant treatment with bupropion and IFN-a theoretically confers an increased seizure risk, especially at higher bupropion doses. 79 In addition, cases of SSRI-induced mania have been reported during IFN-a therapy, including one HCV patient treated with citalopram 20 mg daily. 92 Studies of malignant melanoma patients demonstrated an increased risk of retinal hemorrhages with paroxetine treatment for IFN-a-MDD; however, more recent studies 93, 94 in HCV patients have not replicated this finding and identified IFN-a as the most likely cause of these ocular changes.
The association between spontaneous bleeding and SSRIs is a concern in HCV patients, as HCV patients may already be at Given the potential complications of antidepressant treatment during HCV treatment, patients and clinicians may wish to limit the duration of antidepressant treatment. No conclusive guidelines exist on when to discontinue antidepressant treatment; however, psychiatric symptoms can persist for more than 6 months post-IFN-a treatment. 67, 97 Based on the limited literature, current recommendations suggest continuing antidepressant treatment for a minimum of 3 months post-IFN-a therapy before implementing a gradual taper. 98
Conclusion
The literature clearly outlines a distinct relation between HCV and mental illness both in untreated and in IFN-a-treated patient populations. Despite revisions to HCV treatment guidelines and comparable HCV treatment response rates in patients suffering from mental illness, psychiatric illness remains a considerable barrier to HCV treatment. The reluctance to offer HCV treatment to patients with a history of mental illness is likely a response to original treatment studies identifying a past psychiatric history, family history of a mood disorder, or history of depression as risk factors for IFN-a-MDD and reflects a failure to translate more recent studies into clinical care. Currently, baseline depressive symptoms pre-HCV treatment appears to be the most reliable risk factor for the development of depression in these patients and highlights the need for regular use of Inflammatory cytokines, abnormal 5-HT metabolism, and personality features may be fundamental components to the pathoetiological model for IFN-a-MDD. Therefore, people with multiple abnormalities across these domains could be identified as at-risk patients for IFN-a-MDD and may require antidepressant prophylaxis. Moreover, the outlined model provides a rationale for treatments targeting specific pathways, which could potentially enhance treatment outcomes for IFN-a-MDD in patients with HCV. Although the proposed pathways underlying IFN-a-MDD are based on preliminary findings, further research is needed to delineate the relation between immune activation, monoamines, and depressive symptomatology.
Preliminary RCTs and open-label studies demonstrate the effectiveness of both prophylactic and symptomatic treatment approaches in depressed HCV patients during immunotherapy. The timing and role of antidepressant therapy should be made on a case-by-case basis; however, preventative intervention with antidepressants may be indicated for patients with elevated pre-IFN-a treatment depressive symptoms or a previous history of IFN-a-MDD. Patients receiving pharmacotherapy for a preexisting MDD should be maintained on antidepressant treatment during their IFN-a treatment course. Ideally, clear cut-off scores for identifying at-risk HCV patients during immunotherapy would be useful to guide IFN-a-MDD treatment approaches. For example, Dieperink et al 32 strongly recommend antidepressant treatment with BDI scores of 15 or more, while Raison et al 98 recommend using BDI scores of more than 17 or CES-D scores of more than 14 as indicators for antidepressant pretreatment during HCV immunotherapy. More rigorous studies are required to establish definitive guidelines for antidepressant pretreatment during IFN-a therapy.
Antidepressant treatment in HCV patients has its own risks for IFN-a treatment. For example, antidepressant drugs commonly cause GI and sleep changes, which may worsen IFN-a side effects and lead to HCV treatment discontinuation. Moreover, universal antidepressant pretreatment would result in nearly two-thirds of HCV patients being exposed unnecessarily to potential antidepressant sequelae during immunotherapy. 18, 32 Therefore, prophylactic antidepressant treatment should be reserved for patients at high risk for IFN-a-MDD and a symptomatic approach should be considered in low-risk patients or in response to patient preference. Several RCTs support the efficacy of SSRIs in the treatment of IFN-a-related depressive symptoms. 18, 64 Larger trials are required to examine the role of novel agents for IFN-a-MDD, such as amantadine and modafinil.
Our systematic review summarizes the existing evidence on the use antidepressants in the treatment of IFN-a-MDD. Reductions in the incidence and morbidity of IFN-a-MDD in HCV patients can be improved by early identification of psychiatric comorbidity, rapid stabilization of depressive symptoms pre-HCV treatment, and regular mental health involvement throughout the course of immunotherapy. Increased rates of HCV treatment referrals and HCV treatment adherence in patients with an underlying mental illness can be achieved using an integrated mental health and medical care model. 30 As the number of HCV-infected people being treated increases in Canada during the next decade, psychiatric stabilization and treatment of IFN-a-induced neuropsychiatric complications, such as depression, will be paramount to the overall success of HCV treatment. 5 The information summarized in this review provides a foundation for approaching IFN-a-MDD and highlights the need for greater research in this area.
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Résumé : Prendre en charge la dépression durant le traitement de l'hépatite C
Objectif : La prévalence de l'infection au virus de l'hépatite C (VHC) au Canada est estimée à 1 % et est prévue s'accroître au cours des dix prochaines années. La maladie mentale, en particulier la dépression, est fréquente chez les patients infectés au VHC et demeure un obstacle au traitement à l'interféron-alpha (IFN-a). Nous résumons les facteurs de risque du trouble dépressif majeur induit par l'interféron-a (TDM-IFN-a) chez les patients du VHC et les données probantes de la prophylaxie antidépressive et du traitement antidépresseur symptomatique de la dépression.
Méthodes : Nous avons cherché dans MEDLINE, EMBASE, et CINAHL des essais contrôlés randomisés ou quasi expérimentaux évaluant la prophylaxie antidépressive et les approches de traitement symptomatique de la dépression se manifestant durant le traitement IFN-a. Les recherches manuelles des références citées dans les articles de synthèse, les séries de cas, et les rapports isolés ont complété notre recherche de la documentation.
Résultats : Un total de 9 essais comportant des approches de traitement prophylactique et symptomatique du TDM-IFN-a sont résumés dans notre étude. Le prétraitement antidépresseur est avantageux pour les patients ayant des symptômes dépressifs élevés au départ, et des antécédents de TDM-IFN-a. Bien que les données probantes soient limitées pour plusieurs agents antidépresseurs, la plupart des données probantes suggèrent que les inhibiteurs spécifiques du recaptage de la sérotonine (ISRS) sont sûrs et efficaces pour traiter les symptômes dépressifs consécutifs au traitement IFN-a.
Conclusion :
Le prétraitement antidépresseur et le traitement symptomatique sont tous deux des stratégies viables pour traiter le TDM-IFN-a. De meilleurs résultats de traitement et une identification précoce de la dépression durant le traitement du VHC peuvent s'obtenir en utilisant une approche intégrée de traitement médical et de santé mentale.
